Naloxone

CLASS

  • opioid receptor antagonist

MECHANISM OF ACTION

  • competitive antagonism at mu, kappa and delta receptors -> prevention of binding to endogenous and exogenous opiate receptors.

PHARMACEUTICS

  • IV, IM, intrathecal, SL

DOSE

  • IV: 0.1-0.2mg
  • SC/IM: 0.2-0.4mg
  • onset: 1-2 minutes
  • duration of action: 15-90 minutes

INDICATIONS

  • reversal of opioid agonists
  • also reverses: clonidine, ACE inhibitors, sodium valproate

ADVERSE EFFECTS

PHARMACOKINETICS

  • Absorption – 2% bioavailability from SL route
  • Distribution – 50% protein bound
  • Metabolism – hepatic
  • Elimination – t ½ = 1hr

CCC Pharmacology Series

CCC Toxicology Series

CCC 700 6

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.